However, the monotherapies of anti-PD-1/PD-L1 or anti-CTLA-4 antibodies failed to prolong OS of advanced-stage HCC in several phase III randomized controlled trials, with objective response rates (ORRs) ranging from 15% to 20% [12,13,14]. The gene discussed is CTLA4; the disease is hepatocellular carcinoma.